ライフサイエンスコーパス: gastroparesis

1 en compared in 177 patients with symptoms of gastroparesis.

2 tained diabetic subjects without symptoms of gastroparesis.

3 es on the morbidity associated with diabetic gastroparesis.

4 e identified county residents with potential gastroparesis.

5 tcomes in diabetic patients with symptoms of gastroparesis.

6 n the gastric wall in patients with diabetic gastroparesis.

7 ost patients with diabetes have a history of gastroparesis.

8 f Kit expression and development of diabetic gastroparesis.

9 tics and other therapeutic interventions for gastroparesis.

10 is a viable option for medically refractory gastroparesis.

11 keted in many countries for the treatment of gastroparesis.

12 ed with a 15-year history of severe isolated gastroparesis.

13 motility disorders, especially patients with gastroparesis.

14 and (3) the pathophysiology and treatment of gastroparesis.

15 oxin A represents a novel technique to treat gastroparesis.

16 to be beneficial in idiopathic and diabetic gastroparesis.

17 /- mice, a well-established genetic model of gastroparesis.

18 ociation (AGA) on Diagnosis and Treatment of Gastroparesis.

19 oved quality of life in patients with severe gastroparesis.

20 ld contribute to the development of diabetic gastroparesis.

21 accelerate gastric emptying in patients with gastroparesis.

22 tric emptying, and symptoms in patients with gastroparesis.

23 nts with diabetes) in patients with diabetic gastroparesis.

24 etic dysfunction leading to constipation and gastroparesis.

25 hese findings indicate the chronic nature of gastroparesis.

26 cells of Cajal (ICCs) is common in diabetic gastroparesis.

27 port the use of nortriptyline for idiopathic gastroparesis.

28 placebo for symptomatic relief in idiopathic gastroparesis.

29 s, clinical presentations, and management of gastroparesis.

30 nitiated to delineate the natural history of gastroparesis.

31 n in 12 patients with diabetic or idiopathic gastroparesis.

32 astric dysrhythmias are each associated with gastroparesis.

33 vity could contribute to the pathogenesis of gastroparesis.

34 n in ICC may directly contribute to diabetic gastroparesis.

35 s are found in the majority of patients with gastroparesis.

36 mpare findings in idiopathic versus diabetic gastroparesis.

37 ies in patients with diabetic and idiopathic gastroparesis.

38 followed a diet suggested for patients with gastroparesis.

39 tinal motility disorders, including diabetic gastroparesis.

40 herapeutic option for patients with diabetic gastroparesis.

41 paresis, and 222 any of the 3 definitions of gastroparesis.

42 sis, 83 met diagnostic criteria for definite gastroparesis, 127 definite plus probable gastroparesis,

43 Of 177 patients with symptoms of gastroparesis, 129 (72.9%) had delayed gastric emptying;

44 Thirty-three patients with chronic gastroparesis (17 diabetic and 16 idiopathic) received c

45 ean ICC counts were reduced in patients with gastroparesis (2.3 vs 5.4 bodies/field; P < .001).

46 pecimens were obtained from 40 patients with gastroparesis (20 diabetic) and matched controls.

47 s decreased in more patients with idiopathic gastroparesis (40%) compared with diabetic patients (20%

48 Among 3604 potential cases of gastroparesis, 83 met diagnostic criteria for definite g

49 For the detection of gastroparesis, a 30-min study of clear liquid gastric-em

50 a symptomatic and premalignant disease, for gastroparesis, a less severe and often treatable disease

51 sex and prevalence of symptoms suggestive of gastroparesis among patients with T2DM in Israel has not

52 Dyspepsia may result from gastroparesis and antral distension.

53 clinical profiles in idiopathic and diabetic gastroparesis and are defining roles of gastric and extr

54 We identified a correlation between diabetic gastroparesis and cardiovascular disease, hypertension,

55 was to describe histologic abnormalities in gastroparesis and compare findings in idiopathic versus

56 gastrointestinal (GI) dysfunctions, such as gastroparesis and constipation, are prodromal to the car

57 in gastric muscles of patients with diabetic gastroparesis and nondiabetic control tissues.

58 red to be the gold standard for detection of gastroparesis and other disorders of gastric motility; S

59 r nausea and other symptoms in patients with gastroparesis and related syndromes.

60 cing seems to be able to improve symptoms of gastroparesis and to accelerate gastric emptying in pati

61 underlying impairments in gastric emptying (gastroparesis) and receptive relaxation, but the specifi

62 te gastroparesis, 127 definite plus probable gastroparesis, and 222 any of the 3 definitions of gastr

63 ormation about motor severity, constipation, gastroparesis, and other parameters.

64 Promising for the treatment of gastroparesis are clonidine, sildenafil, and intrapylori

65 It is suggested that symptoms related to gastroparesis are more common in female than in male pat

66 nges associated with diabetic and idiopathic gastroparesis are not well described.

67 od of 2.1 years, 28% of patients treated for gastroparesis at centers of expertise had reductions in

68 initiation and propagation of slow waves in gastroparesis because research tools have lacked spatial

69 d diabetic subjects with classic symptoms of gastroparesis but negative scintigraphy.

70 Gastroparesis can lead to food aversion, poor oral intak

71 Gastroparesis can produce various symptoms in patients w

72 oms, based on a decrease of 1 or more in the gastroparesis cardinal symptom index (GCSI) score after

73 ompleted a demographic questionnaire and the Gastroparesis Cardinal Symptom Index (GCSI).

74 moderate to severe symptom scores using the Gastroparesis Cardinal Symptom Index (GCSI).

75 normal, 85.75 minutes), recent vomiting, and gastroparesis cardinal symptom index-daily diary scores

76 pment for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (i

77 f Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium (GpCRC), comp

78 f Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium Gastroparesis

79 f Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium Registry.

80 ion in symptom severity (measured by the 0-5 Gastroparesis Clinical Symptom Index) for nausea (1.8 vs

81 and also improved other symptoms of diabetic gastroparesis compared with placebo.

82 nutritional consultation after the onset of gastroparesis; consultation was more likely among patien

83 Diabetic gastroparesis (delayed gastric emptying) is a well-recog

84 agnostic definitions were used: (1) definite gastroparesis, delayed gastric emptying by standard scin

85 that Kit expression is lost during diabetic gastroparesis due to increased levels of oxidative stres

86 Furthermore, patients with diabetic gastroparesis express mRNA for a previously unknown vari

87 This review provides updated information on gastroparesis focusing on new findings from the past few

88 cidence per 100,000 person-years of definite gastroparesis for the years 1996-2006 was 2.4 (95% confi

89 Gastroparesis (Gp) is a poorly understood chronic gastro

90 Dietary deficiencies in gastroparesis have been clarified.

91 Many patients with gastroparesis have diets deficient in calories, vitamins

92 Idiopathic gastroparesis (IG) is a common but poorly understood con

93 ne the incidence, prevalence, and outcome of gastroparesis in the community.

94 ology, diagnostic evaluation, and therapy of gastroparesis in the past several years has offered insi

95 (type 1 and type 2) with classic symptoms of gastroparesis (including early satiety, postprandial ful

96 patient outcomes for trials of therapies for gastroparesis, including potential additional trials for

97 CUNV were observed to be similar to those of gastroparesis, indicating that they could be spectra of

98 ge was associated with a higher incidence of gastroparesis, intra-abdominal fluid collection, intra-a

99 Diabetic gastroparesis involves neuropathy, myopathy, and depleti

100 Gastroparesis is a chronic clinical syndrome characteriz

101 PURPOSE OF REVIEW: Gastroparesis is a common disorder that produces symptom

102 BACKGROUND & AIMS: Gastroparesis is a complication of diabetes with few tre

103 e importance of glycemic control in diabetic gastroparesis is a focus of current investigation.

104 Gastroparesis is a well-recognized complication of diabe

105 Gastroparesis is an important complication of diabetes.

106 Gastroparesis is an uncommon condition in the community

107 Gastroparesis is increasingly recognized as a complicati

108 ed to reduce the aspiration risk of diabetic gastroparesis is likely over-utilized and may only be in

109 lence and severity of symptoms suggestive of gastroparesis is particularly high among obese females w

110 The pathophysiological basis of diabetic gastroparesis is poorly understood, in large part due to

111 Gastroparesis is therefore likely to be a heterogeneous

112 The epidemiology of gastroparesis is unknown.

113 usea and vomiting caused by gastroparesis or gastroparesis-like syndrome, aprepitant did not reduce t

114 usea and vomiting caused by gastroparesis or gastroparesis-like syndrome.

115 Symptomatic benefit in gastroparesis may derive more from improved accommodatio

116 ted in patients with CUNV than in those with gastroparesis (mean, 3.5 vs 2.3 bodies/field, respective

117 We studied adult patients with gastroparesis (of diabetic or idiopathic type) enrolled

118 slow-wave initiation and conduction occur in gastroparesis, often at normal frequency, which could be

119 Patients with gastroparesis on oral intake (N = 305) were enrolled in

120 s with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome, aprepitant

121 s with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome.

122 mptying has added value for the diagnosis of gastroparesis over a study of solid emptying alone.

123 Nine patients with gastroparesis participated in this study.

124 The age-adjusted prevalence of definite gastroparesis per 100,000 persons on January 1, 2007, wa

125 hilic esophagitis, functional dyspepsia, and gastroparesis, posing a challenge for patient management

126 strointestinal tract that include dysphagia, gastroparesis, prolonged gastrointestinal transit time,

127 ive treatment is available for patients with gastroparesis refractory to standard medical therapy.

128 f Diabetes and Digestive and Kidney Diseases Gastroparesis Registry and completed diet questionnaires

129 s Gastroparesis Clinical Research Consortium Gastroparesis Registry, seen every 16 weeks and treated

130 n a clinical trial of patients with diabetic gastroparesis, relamorelin (10 mug twice daily) signific

131 Gastroparesis remains a challenging syndrome to manage,

132 y of full thickness gastric tissue in severe gastroparesis shows heterogeneous enteric neuronal, smoo

133 electrical mapping to quantify and classify gastroparesis slow-wave abnormalities in spatiotemporal

134 of diabetic patients with moderate to severe gastroparesis symptoms (DG).

135 Medical history, gastroparesis symptoms, answers to the Block Food Freque

136 e nausea, satiety, constipation, and overall gastroparesis symptoms.

137 and more severe loss of appetite and overall gastroparesis symptoms.

138 dies are more sensitive for the detection of gastroparesis than are liquid studies; thus, liquid stud

139 d splicing of Ano1 in patients with diabetic gastroparesis that alter the electrophysiological proper

140 Among patients with idiopathic gastroparesis, the use of nortriptyline compared with pl

141 of CUNV substantially overlap with those of gastroparesis, therefore the diseases may share pathophy

142 NTS: The NORIG (Nortriptyline for Idiopathic Gastroparesis) trial, a 15-week multicenter, parallel-gr

143 r upper gastrointestinal study; (3) possible gastroparesis, typical symptoms alone or delayed gastric

144 ymptoms for more than 3 months; (2) probable gastroparesis, typical symptoms and food retention on en

145 stimulation for the treatment of symptomatic gastroparesis unresponsive to standard medical therapy.

146 disorders such as irritable bowel syndrome, gastroparesis, urinary incontinence and cardiac arrhythm

147 One hundred thirty patients with idiopathic gastroparesis were enrolled between March 2009 and June

148 Symptoms of gastroparesis were substantially reduced at the end of t

149 h those of controls as well as patients with gastroparesis who were studied previously by identical m

150 quantify GES IMD; and correlate symptoms of gastroparesis with IMD and gastric emptying.

151 5 y; 88% with type 2 diabetes) with diabetic gastroparesis with moderate to severe symptoms and delay

152 s were found between diabetic and idiopathic gastroparesis with the exception of nNOS expression, whi